Skye Bioscience ( (SKYE) ) just unveiled an announcement.
Skye Bioscience has announced the appointment of Paul Grayson as the new Chairman of the Board, signaling a strategic move to enhance governance and oversight. With his extensive experience in biotechnology, Grayson is set to guide Skye’s development of nimacimab, a promising therapy targeting metabolic diseases like obesity. This leadership change comes as Skye continues its focus on innovative treatments and navigates its clinical trials, aiming for significant breakthroughs in metabolic health.
See more data about SKYE stock on TipRanks’ Stock Analysis page.
